vs
Side-by-side financial comparison of Apellis Pharmaceuticals, Inc. (APLS) and UNIVERSAL INSURANCE HOLDINGS, INC. (UVE). Click either name above to swap in a different company.
UNIVERSAL INSURANCE HOLDINGS, INC. is the larger business by last-quarter revenue ($393.6M vs $199.9M, roughly 2.0× Apellis Pharmaceuticals, Inc.). UNIVERSAL INSURANCE HOLDINGS, INC. runs the higher net margin — 13.8% vs -29.5%, a 43.3% gap on every dollar of revenue. On growth, UNIVERSAL INSURANCE HOLDINGS, INC. posted the faster year-over-year revenue change (-0.3% vs -5.9%). Over the past eight quarters, Apellis Pharmaceuticals, Inc.'s revenue compounded faster (7.7% CAGR vs 1.7%).
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies that modulate the complement system to address serious unmet medical needs. Its core products target ophthalmic conditions like geographic atrophy secondary to age-related macular degeneration, as well as rare hematological and autoimmune disorders, with primary operations in the United States and European markets.
New York Life Insurance Company (NYLIC), most commonly known as New York Life, is the second-largest life insurance company and the largest mutual life insurance company in the United States, and is ranked #69 on the 2025 Fortune 500 list of the largest U.S. corporations by total revenue. In 2025, NYLIC achieved the best possible ratings by the four independent rating companies. Other New York Life affiliates provide an array of securities products and services, as well as institutional and r...
APLS vs UVE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $199.9M | $393.6M |
| Net Profit | $-59.0M | $54.3M |
| Gross Margin | — | — |
| Operating Margin | -25.6% | — |
| Net Margin | -29.5% | 13.8% |
| Revenue YoY | -5.9% | -0.3% |
| Net Profit YoY | -62.2% | — |
| EPS (diluted) | $-0.40 | $1.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $393.6M | ||
| Q4 25 | $199.9M | $407.9M | ||
| Q3 25 | $458.6M | $401.0M | ||
| Q2 25 | $178.5M | $400.1M | ||
| Q1 25 | $166.8M | $394.9M | ||
| Q4 24 | $212.5M | $384.8M | ||
| Q3 24 | $196.8M | $387.6M | ||
| Q2 24 | $199.7M | $380.2M |
| Q1 26 | — | $54.3M | ||
| Q4 25 | $-59.0M | $66.6M | ||
| Q3 25 | $215.7M | $39.8M | ||
| Q2 25 | $-42.2M | $35.1M | ||
| Q1 25 | $-92.2M | $41.4M | ||
| Q4 24 | $-36.4M | $6.0M | ||
| Q3 24 | $-57.4M | $-16.2M | ||
| Q2 24 | $-37.7M | $35.4M |
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 21.7% | ||
| Q3 25 | 48.7% | 13.2% | ||
| Q2 25 | -18.6% | 11.6% | ||
| Q1 25 | -50.0% | 14.0% | ||
| Q4 24 | -12.3% | 1.9% | ||
| Q3 24 | -24.0% | -4.7% | ||
| Q2 24 | -14.7% | 12.6% |
| Q1 26 | — | 13.8% | ||
| Q4 25 | -29.5% | 16.3% | ||
| Q3 25 | 47.0% | 9.9% | ||
| Q2 25 | -23.6% | 8.8% | ||
| Q1 25 | -55.3% | 10.5% | ||
| Q4 24 | -17.1% | 1.6% | ||
| Q3 24 | -29.2% | -4.2% | ||
| Q2 24 | -18.9% | 9.3% |
| Q1 26 | — | $1.88 | ||
| Q4 25 | $-0.40 | $2.29 | ||
| Q3 25 | $1.67 | $1.38 | ||
| Q2 25 | $-0.33 | $1.21 | ||
| Q1 25 | $-0.74 | $1.44 | ||
| Q4 24 | $-0.30 | $0.23 | ||
| Q3 24 | $-0.46 | $-0.57 | ||
| Q2 24 | $-0.30 | $1.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $466.2M | $595.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $370.1M | $584.7M |
| Total Assets | $1.1B | $2.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $595.8M | ||
| Q4 25 | $466.2M | $408.9M | ||
| Q3 25 | $479.2M | $405.1M | ||
| Q2 25 | $370.0M | $367.1M | ||
| Q1 25 | $358.4M | $398.2M | ||
| Q4 24 | $411.3M | $259.4M | ||
| Q3 24 | $396.9M | $333.7M | ||
| Q2 24 | $360.1M | $283.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $100.5M | ||
| Q3 25 | — | $100.7M | ||
| Q2 25 | — | $100.9M | ||
| Q1 25 | — | $101.1M | ||
| Q4 24 | — | $101.2M | ||
| Q3 24 | — | $101.4M | ||
| Q2 24 | — | $101.6M |
| Q1 26 | — | $584.7M | ||
| Q4 25 | $370.1M | $551.0M | ||
| Q3 25 | $401.2M | $495.0M | ||
| Q2 25 | $156.3M | $457.8M | ||
| Q1 25 | $164.2M | $422.4M | ||
| Q4 24 | $228.5M | $373.3M | ||
| Q3 24 | $237.1M | $400.2M | ||
| Q2 24 | $264.3M | $393.2M |
| Q1 26 | — | $2.8B | ||
| Q4 25 | $1.1B | $2.8B | ||
| Q3 25 | $1.1B | $3.1B | ||
| Q2 25 | $821.4M | $3.3B | ||
| Q1 25 | $807.3M | $2.7B | ||
| Q4 24 | $885.1M | $2.8B | ||
| Q3 24 | $901.9M | $2.7B | ||
| Q2 24 | $904.5M | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.18× | ||
| Q3 25 | — | 0.20× | ||
| Q2 25 | — | 0.22× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | 0.25× | ||
| Q2 24 | — | 0.26× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.2M | — |
| Free Cash FlowOCF − Capex | $-14.3M | — |
| FCF MarginFCF / Revenue | -7.1% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $45.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $381.5M | ||
| Q3 25 | $108.5M | $62.4M | ||
| Q2 25 | $4.4M | $106.2M | ||
| Q1 25 | $-53.4M | $186.8M | ||
| Q4 24 | $19.4M | $137.4M | ||
| Q3 24 | $34.1M | $82.6M | ||
| Q2 24 | $-8.3M | $73.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $377.1M | ||
| Q3 25 | $108.3M | $61.3M | ||
| Q2 25 | $4.4M | $105.2M | ||
| Q1 25 | $-53.4M | $185.5M | ||
| Q4 24 | $19.3M | $130.0M | ||
| Q3 24 | — | $81.0M | ||
| Q2 24 | $-8.4M | $71.6M |
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 92.4% | ||
| Q3 25 | 23.6% | 15.3% | ||
| Q2 25 | 2.5% | 26.3% | ||
| Q1 25 | -32.0% | 47.0% | ||
| Q4 24 | 9.1% | 33.8% | ||
| Q3 24 | — | 20.9% | ||
| Q2 24 | -4.2% | 18.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 1.1% | ||
| Q3 25 | 0.0% | 0.3% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.0% | 1.9% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | 0.0% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.73× | ||
| Q3 25 | 0.50× | 1.57× | ||
| Q2 25 | — | 3.03× | ||
| Q1 25 | — | 4.51× | ||
| Q4 24 | — | 22.82× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
UVE
Segment breakdown not available.
